Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumab.
Although effective in the treatment of immunodysregulatory diseases such as psoriasis, targeted immunosuppressive agents may confer risks of both enhanced susceptibility to infection and decreased responsiveness to vaccination. In a recent study, Krueger et al. (this issue) investigated these issues by testing the immune response to both a model antigen and a therapeutic vaccination in psoriasis patients during and after treatment with an LFA-1 inhibitor, efalizumab.
Marmon
Shana
S
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA.
Strober
Bruce E
BE
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA. Electronic address: strober@nyc.rr.com.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D010584:Bacteriophage phi X 174 / Q000276:immunology; D040881:CD11a Antigen / Q000378:metabolism; D006801:Humans; D007109:Immunity; D007074:Immunoglobulin G / Q000378:metabolism; D007075:Immunoglobulin M / Q000378:metabolism; D007165:Immunosuppression Therapy; D016169:Lymphocyte Function-Associated Antigen-1 / Q000276:immunology; D022242:Pneumococcal Vaccines / Q000494:pharmacology; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013745:Tetanus Toxoid / Q000494:pharmacology; D014612:Vaccines / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D040881:CD11a Antigen; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016169:Lymphocyte Function-Associated Antigen-1; D022242:Pneumococcal Vaccines; D013745:Tetanus Toxoid; D014612:Vaccines; C472181:efalizumab